Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Voyager Therapeutics, Inc. develops genetic medicines and other neurotherapeutics for neurological diseases, with company updates focused on its CNS pipeline and delivery platforms. Recurring news covers the TRACER AAV capsid discovery platform, intravenous gene-therapy research, Voyager NeuroShuttle nonviral delivery work, and programs addressing Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, ALS, frontotemporal dementia and other central nervous system disorders.
Company announcements also cover tau-focused assets such as VY1706 and VY7523, small-molecule discovery collaboration targeting TDP-43 pathology, scientific conference presentations, and periodic financial and operating results. Voyager’s updates frequently connect pipeline spending, collaboration revenue, partner programs and balance-sheet resources with its genetic-medicine development strategy.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in two upcoming investor conferences in September 2024:
- The Wells Fargo 2024 Healthcare Conference in Boston, with a fireside chat on September 5 at 1:30 p.m. ET
- The Baird 2024 Global Healthcare Conference in New York City, featuring a fireside chat on September 11 at 1:25 p.m. ET
Webcasts of the presentations will be available on the Investors section of Voyager's website and archived for at least 30 days. This announcement highlights Voyager's engagement with investors and its commitment to sharing updates on its progress in the field of neurogenetic medicine.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. The company will engage in a fireside chat on August 14, 2024, at 9:30 a.m. ET.
Investors and interested parties can access a webcast of the presentation through the Investors section of Voyager's website at ir.voyagertherapeutics.com. For those unable to attend live, a replay of the webcast will be available on the company's website for a minimum of 30 days following the event.
Voyager Therapeutics (Nasdaq: VYGR) reported its Q2 2024 financial results and operational progress. Key highlights include:
1. Initiated Phase 1a single ascending dose trial of anti-tau antibody VY7523 for Alzheimer's disease, with top-line data expected in H1 2025.
2. Advanced three CNS gene therapy programs towards INDs in 2025.
3. Appointed Nathan Jorgensen, Ph.D., as CFO.
4. Strong cash position of $371 million as of June 30, 2024, providing runway into 2027.
5. Q2 2024 collaboration revenue increased to $29.6 million, up from $4.9 million in Q2 2023.
6. Net loss decreased to $10.1 million in Q2 2024, compared to $22.2 million in Q2 2023.
7. R&D expenses increased to $34.5 million in Q2 2024, up from $22.0 million in Q2 2023.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its upcoming second quarter 2024 financial results release and conference call. The company will report its Q2 2024 financial and operating results after market close on Tuesday, August 6, 2024. Following this, Voyager will host a conference call and webcast at 4:30 p.m. ET.
Interested participants can register for the telephone conference in advance through a provided link. A live webcast will be available on the Investors section of Voyager's website, with a replay accessible for at least 30 days after the call.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focusing on neurogenetic medicines, has granted inducement awards to new employee Eric Hall, Ph.D., M.B.A. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), include:
1. A non-qualified stock option for 36,000 shares, effective July 22, 2024, with a ten-year term and an exercise price of $8.77 per share. It vests over four years: 25% after one year, then 75% monthly over three years.
2. Restricted stock units for 18,000 shares, effective October 1, 2024, vesting annually in equal installments over three years.
Both awards are subject to Dr. Hall's continued employment with Voyager and the terms of their respective award agreements.
Voyager Therapeutics (Nasdaq: VYGR) announced the induction of Nathan Jorgensen, Ph.D., M.B.A., into their team with a notable employment agreement. This agreement includes a non-qualified stock option for 200,000 shares and restricted stock units (RSUs) for 80,000 shares as part of the inducement process, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4). The stock option, effective July 8, 2024, carries an exercise price of $7.79 per share, matching the closing price on the effective date. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% in equal monthly installments over the next three years. The RSUs will vest annually in equal installments over three years starting October 1, 2024. These equity awards are contingent upon Dr. Jorgensen's ongoing employment with Voyager and are subject to specific award agreements.
Voyager Therapeutics (Nasdaq: VYGR), a biotech company specializing in neurogenetic medicines, will participate in two virtual investor conferences in June 2024.
The company will present at the TD Cowen Genetic Medicines & RNA Summit on June 20 at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27 at 7:00 a.m. ET. Both presentations will be webcasted and available on Voyager’s investor website, with replays accessible for at least 30 days.
Voyager Therapeutics (Nasdaq: VYGR) announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer, effective July 8, 2024. Jorgensen, bringing extensive experience in investment banking, healthcare investing, and biotech operations, previously served as CFO at Vor Biopharma. He raised over $400 million in financings and managed various operational domains. Voyager's CEO, Alfred W. Sandrock, Jr., emphasized Jorgensen's blend of strategic leadership and neuroscience expertise as important for advancing their neurotherapeutics pipeline. Jorgensen expressed enthusiasm for Voyager's innovative platform and its potential to overcome neurology delivery challenges.
Voyager Therapeutics announced the dosing of the first participants in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigational anti-tau antibody designed to inhibit the spread of pathological tau in Alzheimer's disease. This randomized, double-blind, placebo-controlled trial aims to assess the safety and pharmacokinetics of VY-TAU01 in healthy adults. Conducted at a single U.S. site, the trial plans to enroll around 48 patients. Data from this trial will inform a Phase 1b multiple ascending dose (MAD) trial in early Alzheimer's patients, expected to begin in 2025, with initial imaging data potentially available by late 2026. Chief Medical Officer Toby Ferguson highlighted this milestone as a testament to Voyager's neurology drug development capabilities.
Voyager Therapeutics reported its first quarter 2024 financial and operating results, highlighting several milestones and future expectations. The company received IND clearance for its anti-tau antibody VY-TAU01 for Alzheimer's disease and plans to start a trial soon. Development candidates were chosen for the GBA1 and Friedreich’s Ataxia gene therapy programs, with potential clinical entries in 2025. Voyager appointed Dr. Toby Ferguson as Chief Medical Officer. The company completed a $100 million public offering and announced a strategic collaboration with Novartis, which included an $80 million upfront payment and $20 million in newly issued equity. Voyager’s cash position is strong at approximately $400 million, providing financial runway into 2027. However, collaboration revenue dropped from $150.5 million in Q1 2023 to $19.5 million in Q1 2024, leading to a net loss of $11.3 million compared to a net income of $124 million in the same period last year. R&D expenses increased due to program-related spending.